

Amendments to the Claims:

Applicants request, without prejudice or disclaimer, that the Examiner cancel claims 2, 3 and 5-13 and add new claims 14-26 as follows. This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1 - 13. (Cancelled)

14. (New) A process for producing a mammal, selected from the group consisting of mouse, pig and cattle, resistant to infection by PRV or BHV-1 viruses, said process comprising the steps of:

- a) constructing a transgene recombinant DNA including at least the coding sequence of a fusion protein of the V domain or the VCC domain of porcine or bovine nectin-1 and the crystallisable fragment of an immunoglobulin selected from the group consisting of human, porcine, bovine or mouse immunoglobulin operably linked to a promoter and regulatory sequences and optional targeting sequences and selectable markers;
- b) introducing said transgene DNA into pronuclei of fertilized zygotes of said mammal by microinjection or into cultured cells of said mammal by electroporation or transfection, and selecting cells having incorporated said transgene DNA in a targeted location by homologous recombination;
- c) transferring into the reproductive tract of a recipient female said microinjected pronuclei of fertilized zygotes, or transferring nuclei of said targeted cells into enucleated oocytes and transferring the reconstructed embryos into the reproductive tract of a recipient female;
- d) selecting among progeny of said recipient female founder transgenic mammals having incorporated said transgene DNA into their genome and expressing said fusion protein; and
- e) breeding said founder transgenic mammals with non-transgenic mammals in successive generations and selecting carriers of said DNA transgene from among the progeny.

15. (New) A process according to claim 14, wherein said immunoglobulin is a gamma type immunoglobulin.

16. (New) A process according to claim 14, wherein one or both of said nectin-1 or said immunoglobulin belong to a homologous species of said mammal.
17. (New) A mammal belonging to a non-human species, wherein said mammal is produced by the process of claim 14.
18. (New) The mammal of claim 17, wherein said immunoglobulin is a gamma type immunoglobulin.
19. (New) The mammal of claim 17, wherein said gamma type immunoglobulin is of a homologous species.
20. (New) A mammal according to claim 17, wherein in that said transgene encodes said VCC domain.
21. (New) A mammal according to claim 17, wherein said mammal belongs to a porcine species and said virus is a PRV virus.
22. (New) A mammal according to claim 17, wherein said mammal belongs to a bovine species and said virus is a BHV-1 virus.
23. (New) A mammal according to claim 17, wherein said mammal contains in its cells' genome a coding transgene for a chimeric protein comprising said V domain or VCC domain of nectin-1 and said crystallisable fragment of an immunoglobulin, in an expression system, said transgene having been inserted in a genome of a germinal line of one of its parents.
24. (New) Genetic material in germplasm essentially derived from said mammal according to claim 17.
25. (New) A process for producing a mammal, selected from the group consisting of mice, pigs and cattle, resistant to infection by PRV or BHV-1 viruses, said process comprising introducing a recombinant DNA encoding a polypeptide comprising the V domain or the VCC domain of porcine or bovine nectin-1 linked or fused to a crystallisable fragment of an immunoglobulin selected from the group consisting of human, porcine, bovine or mouse immunoglobulin, by insertion or homologous recombination into the genome of said mammal, wherein said introduced recombinant DNA expresses said polypeptide.
26. (New) A mammal selected from the group consisting of mice, pigs and cattle, wherein said mammal is an offspring of the mammal produced by the process of claim 25.